FDA is revising the medical device and
biological product labeling regulations to provide that a
stand-alone symbol is allowed to be used in device labeling if the
symbol is established in a standard developed by a standards
development organization (SDO); is contained in a standard that FDA
recognizes for use in the labeling for devices, or, alternatively,
is determined by the manufacturer to be likely to be read and
understood by the ordinary individual under customary conditions of
purchase and use; and is explained in a paper or electronic symbols
glossary that is included in the labeling for the device and the
labeling on or within the package containing the device bears a
prominent and conspicuous statement about the location of the
symbols glossary. The final rule also specifies that the use of
symbols, accompanied by adjacent explanatory text continues to be
permitted. Additionally, FDA is revising its prescription device
labeling regulations to authorize the use of the symbol statement
“Rx only” in the labeling for prescription devices.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.